MedTrace Logo

Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein

NCT00463749 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2008-07-08

No results posted yet for this study

Summary

Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration.

In primary percutaneous intervention for infarction hydration is not possible. Therefore Acetylcystein might prevent contrast dye induced nephropathy.

Furthermore, it might reduce infarct size as a result of its antioxidant properties.

Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and infarct size.

Conditions

Interventions

DRUG

Acetylcystein

high-dose N-Acetylcystein during PCI and for 2/day for 2 days

DRUG

Placebo

NaCl as placebo

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Holger Thiele, MD · Heart Center Leipzig - University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-02-29
Completion
2008-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00463749 on ClinicalTrials.gov